Loading…
Comprehensive Fentanyl Control Act
Legislative Progress
Introduced
March 29, 2017
Latest Action
April 21, 2017
Primary Sponsor
Daniel M. Donovan, Jr.Republican(NY)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
70pct
23d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Comprehensive Fentanyl Control Act This bill amends the Controlled Substances Act to modify the drug quantity thresholds that trigger a mandatory minimum prison term for a defendant who manufactures, distributes, or possesses with intent to distribute fentanyl. It also establishes a consecutive mandatory prison term for a defendant who commits a drug offense involving a detectable amount of heroin or fentanyl. The bill establishes a rebuttable presumption that the illegal manufacture of a controlled substance that contains a detectable amount of heroin or fentanyl creates a substantial risk of harm to human life. The Drug Enforcement Administration may temporarily place a drug or substance into schedule I based on a finding: (1) that the drug or substance satisfies the criteria for being a synthetic opioid, and (2) that adding it will prevent abuse or misuse. The bill makes it a crime to knowingly mail to an unauthorized person equipment that may be used to manufacture counterfeit controlled substances. A violator is subject to criminal penalties. Finally, it makes it a crime to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, a synthetic opioid that is not clearly labeled. A violator is subject to criminal and civil penalties.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2018 · fourth_quarter · Alcohol and Drug Abuse
H.R. 714 Use of Medicinal Marihuana H.R. 715 Rescheduling of Marihuana H.R. 975 Controlled Substances Act Application to Marihuana H.R. 1781 Synthetic Opioids H.R. 1824 Federal and State Marijuana Policy Gap Reduction S. 581 Opioids Addiction Information in Medical Records S. 780 Federal and State Marijuana Policy Gap Reduction H.R. 2020 Rescheduling of Marijuana H.R. 2063 Opioid Dispensary Registration Training Condition S. 1078 FDA Opioid Approval Procedures S. 1079 FDA Opioid Approval and Revocation S. 1327 Controlled Substance Analogues Regulation H.R. 3374 Drunk Driving H.R. 3534 State Legalized Marijuana S. 1553 Schedule 1 Controlled Substances S. 1554 Controlled Substance Continuing Education S. 1689 Controlled Substances Act H.R. 3964 Registration Requirements for Prescribers of Opioids H.R. 4482 Opioid Abuse and Addiction S. 2008 Opioid Epidemic and Drug Sample Backlogs H.R. 4903 Opioid Usage Reduction Best Practices Study H.R. 4922 Fentanyl Analogues H.R. 5109 Opioid Epidemic Distribution of Resources S. 2437 Opioid Grant Program S. 2440 Opioid Epidemic S. 2535 Opioid Quotas H.R. 5473 Alternative Methods for Data Collection H.R. 5581 Prescribers of Controlled Substances H.R. 5590 Medicare and Opioid Addictions H.R. 5723 Medicare Payment Advisory Commission H.R. 5782 Pharmaceutical Company Accountability S. 2680 Opioid Crisis S. 2691 Pharmaceutical Companies and Illegal Marketing S. 2729 Prevention of Prescription Opioid Misuse S. 2838 Reporting Information on Distribution of Opioids S. 2848 Controlled Substances and Alcohol Testing H.R. 6491 Reporting of Information on Distribution of Opioids H.R. 6608 Prescription Drug Monitoring Programs Data Collection H.R. 5812 Controlled Substance Overdose Prevention Activities
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Oversight and Government Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $1,030,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Credit Union Administration (NCUA), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2018 · third_quarter · Alcohol and Drug Abuse
H.R. 714 Use of Medicinal Marihuana H.R. 715 Rescheduling of Marihuana H.R. 975 Controlled Substances Act Application to Marihuana H.R. 1781 Synthetic Opioids H.R. 1824 Federal and State Marijuana Policy Gap Reduction S. 581 Opioids Addiction Information in Medical Records S. 780 Federal and State Marijuana Policy Gap Reduction H.R. 2020 Rescheduling of Marijuana H.R. 2063 Opioid Dispensary Registration Training Condition S. 1078 FDA Opioid Approval Procedures S. 1079 FDA Opioid Approval and Revocation S. 1327 Controlled Substance Analogues Regulation H.R. 3374 Drunk Driving H.R. 3534 State Legalized Marijuana S. 1553 Schedule 1 Controlled Substances S. 1554 Controlled Substance Continuing Education S. 1689 Controlled Substances Act H.R. 3964 Registration Requirements for Prescribers of Opioids H.R. 4482 Opioid Abuse and Addiction S. 2008 Opioid Epidemic and Drug Sample Backlogs H.R. 4903 Opioid Usage Reduction Best Practices Study H.R. 4922 Fentanyl Analogues H.R. 5109 Opioid Epidemic Distribution of Resources S. 2437 Opioid Grant Program S. 2440 Opioid Epidemic S. 2535 Opioid Quotas H.R. 5473 Alternative Methods for Data Collection H.R. 5581 Prescribers of Controlled Substances H.R. 5590 Medicare and Opioid Addictions H.R. 5723 Medicare Payment Advisory Commission H.R. 5782 Pharmaceutical Company Accountability S. 2680 Opioid Crisis S. 2691 Pharmaceutical Companies and Illegal Marketing S. 2729 Prevention of Prescription Opioid Misuse S. 2838 Reporting Information on Distribution of Opioids S. 2848 Controlled Substances and Alcohol Testing H.R. 6491 Reporting of Information on Distribution of Opioids H.R. 6608 Prescription Drug Monitoring Programs Data Collection H.R. 5812 Controlled Substance Overdose Prevention Activities
Client expense: $1,070,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2018 · second_quarter · Alcohol and Drug Abuse
H.R. 714 Use of Medicinal Marihuana H.R. 715 Rescheduling of Marihuana H.R. 975 Controlled Substances Act Application to Marihuana H.R. 1781 Synthetic Opioids H.R. 1824 Federal and State Marijuana Policy Gap Reduction S. 581 Opioids Addiction Information in Medical Records S. 780 Federal and State Marijuana Policy Gap Reduction H.R. 2020 Rescheduling of Marijuana H.R. 2063 Opioid Dispensary Registration Training Condition S. 1078 FDA Opioid Approval Procedures S. 1079 FDA Opioid Approval and Revocation S. 1327 Controlled Substance Analogues Regulation H.R. 3374 Drunk Driving H.R. 3534 State Legalized Marijuana S. 1553 Schedule 1 Controlled Substances S. 1554 Controlled Substance Continuing Education S. 1689 Controlled Substances Act H.R. 3964 Registration Requirements for Prescribers of Opioids H.R. 4482 Opioid Abuse and Addiction S. 2008 Opioid Epidemic and Drug Sample Backlogs H.R. 4903 Opioid Usage Reduction Best Practices Study H.R. 4922 Fentanyl Analogues H.R. 5109 Opioid Epidemic Distribution of Resources S. 2437 Opioid Grant Program S. 2440 Opioid Epidemic S. 2535 Opioid Quotas **Issues lobbied without specific bill number: Workers' Compensation Medicare Set-Aside H.R. 5473 Alternative Methods for Data Collection H.R. 5581 Prescribers of Controlled Substances H.R. 5590 Medicare and Opioid Addictions H.R. 5723 Medicare Payment Advisory Commission H.R. 5782 Pharmaceutical Company Accountability S. 2680 Opioid Crisis S. 2691 Pharmaceutical Companies and Illegal Marketing S. 2729 Prevention of Prescription Opioid Misuse S. 2838 Reporting Information on Distribution of Opioids S. 2848 Controlled Substances and Alcohol Testing
Client expense: $1,590,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2018 · first_quarter · Alcohol and Drug Abuse
H.R. 714 Use of Medicinal Marihuana H.R. 715 Rescheduling of Marihuana H.R. 975 Controlled Substances Act Application to Marihuana H.R. 1781 Synthetic Opioids H.R. 1824 Federal and State Marijuana Policy Gap Reduction S. 581 Opioids Addiction Information in Medical Records S. 780 Federal and State Marijuana Policy Gap Reduction H.R. 2020 Rescheduling of Marijuana H.R. 2063 Opioid Dispensary Registration Training Condition S. 1078 FDA Opioid Approval Procedures S. 1079 FDA Opioid Approval and Revocation S. 1327 Controlled Substance Analogues Regulation H.R. 3374 Drunk Driving H.R. 3534 State Legalized Marijuana S. 1553 Schedule 1 Controlled Substances S. 1554 Controlled Substance Continuing Education S. 1689 Controlled Substances Act H.R. 3964 Registration Requirements for Prescribers of Opioids H.R. 4482 Opioid Abuse and Addiction S. 2008 Opioid Epidemic and Drug Sample Backlogs H.R. 4903 Opioid Usage Reduction Best Practices Study H.R. 4922 Fentanyl Analogues H.R. 5109 Opioid Epidemic Distribution of Resources S. 2437 Opioid Grant Program S. 2440 Opioid Epidemic S. 2535 Opioid Quotas **Issues lobbied without specific bill number: Workers' Compensation Medicare Set-Aside
Client expense: $1,220,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · fourth_quarter · Alcohol and Drug Abuse
H.R. 714 Use of Medicinal Marihuana H.R. 715 Rescheduling of Marihuana H.R. 975 Controlled Substances Act Application to Marihuana H.R. 1781 Synthetic Opioids H.R. 1824 Federal and State Marijuana Policy Gap Reduction S. 581 Opioids Addiction Information in Medical Records S. 780 Federal and State Marijuana Policy Gap Reduction H.R. 2020 Rescheduling of Marijuana H.R. 2063 Opioid Dispensary Registration Training Condition S. 1078 FDA Opioid Approval Procedures S. 1079 FDA Opioid Approval and Revocation S. 1327 Controlled Substance Analogues Regulation H.R. 3374 Drunk Driving H.R. 3534 State Legalized Marijuana S. 1553 Schedule 1 Controlled Substances S. 1554 Controlled Substance Continuing Education S. 1689 Controlled Substances Act H.R. 3964 Registration Requirements for Prescribers of Opioids H.R. 4482 Opioid Abuse and Addiction S. 2008 Opioid Epidemic and Drug Sample Backlogs
Client expense: $1,390,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · third_quarter · Alcohol and Drug Abuse
H.R. 714 Use of Medicinal Marihuana H.R. 715 Rescheduling of Marihuana H.R. 975 Controlled Substances Act Application to Marihuana H.R. 1781 Synthetic Opioids H.R. 1824 Federal and State Marijuana Policy Gap Reduction S. 581 Opioids Addiction Information in Medical Records S. 780 Federal and State Marijuana Policy Gap Reduction H.R. 2020 Rescheduling of Marijuana H.R. 2063 Opioid Dispensary Registration Training Condition S. 1078 FDA Opioid Approval Procedures S. 1079 FDA Opioid Approval and Revocation S. 1327 Controlled Substance Analogues Regulation H.R. 3374 Drunk Driving H.R. 3534 State Legalized Marijuana S. 1553 Schedule 1 Controlled Substances S. 1554 Controlled Substance Continuing Education S. 1689 Controlled Substances Act
Client expense: $1,250,000 · Firm income: Not reported
2017 · second_quarter · Alcohol and Drug Abuse
H.R. 714 Use of Medicinal Marihuana H.R. 715 Rescheduling of Marihuana H.R. 975 Controlled Substances Act Application to Marihuana H.R. 1781 Synthetic Opioids H.R. 1824 Federal and State Marijuana Policy Gap Reduction S. 581 Opioids Addiction Information in Medical Records S. 780 Federal and State Marijuana Policy Gap Reduction H.R. 2020 Rescheduling of Marijuana H.R. 2063 Opioid Dispensary Registration Training Condition S. 1078 FDA Opioid Approval Procedures S. 1079 FDA Opioid Approval and Revocation S. 1327 Controlled Substance Analogues Regulation
Client expense: $1,460,000 · Firm income: Not reported
| Republican |
| NC |
| Thomas J. Rooney | Republican | FL |
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE